Last reviewed · How we verify
thyrotropin-releasing hormone
Thyrotropin-releasing hormone stimulates the release of thyroid-stimulating hormone (TSH) from the anterior pituitary gland.
Thyrotropin-releasing hormone stimulates the release of thyroid-stimulating hormone (TSH) from the anterior pituitary gland. Used for Hypothyroidism due to insufficient TSH production, Diagnostic testing of pituitary function.
At a glance
| Generic name | thyrotropin-releasing hormone |
|---|---|
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Drug class | hormone |
| Target | TRH receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
TRH acts on the thyrotroph cells in the anterior pituitary gland by binding to its G-protein coupled receptors, leading to increased intracellular calcium levels and subsequent secretion of TSH, which then regulates thyroid hormone production.
Approved indications
- Hypothyroidism due to insufficient TSH production
- Diagnostic testing of pituitary function
Common side effects
- Nausea
- Headache
Key clinical trials
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment (NA)
- Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)
- To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001) (PHASE3)
- Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer (PHASE1)
- Follicle Size and Oocyte Development (NA)
- Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter (PHASE2)
- Mechanistic Study of Subclinical Hypothyroidism In the Elderly (NA)
- A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |